Status:
COMPLETED
The Minimum Effective Dose (ED90) of Liposomal Bupivacaine for Preserving Motor Function
Lead Sponsor:
Affiliated Hospital of Jiaxing University
Conditions:
Motion Sickness
Eligibility:
All Genders
41-65 years
Phase:
PHASE4
Brief Summary
Explore the minimum effective dose of liposomal bupivacaine for preserving motor function
Detailed Description
Our research group plans to conduct a dose exploration experiment, using a biased coin design sequential method to explore the 90% minimum effective dose of bupivacaine liposomes for preserving motor ...
Eligibility Criteria
Inclusion
- Age 41-65 years ASA physical condition 1-3 BMI 18-30 kg/m2 undergoing arthroscopic shoulder surgery
Exclusion
- Inability to consent to the study pregnancy allergy to local anesthetics preexisting neuropathy cervical pathologies (i.e., herniated disc, myelopathy) chronic pain syndromes (defined as reflex sympathetic dystrophy or complex regional pain syndrome) severe respiratory conditions psychiatric or cognitive disorders that prohibit patients from adhering to the study protocol history of drug or alcohol abuse chronic opioid use (longer than 3 months or daily morphine equivalents more than 5mg/day for 1 month) contraindication for general anesthesia and/or interscalene nerve block and planned open shoulder arthrotomies Muscle related diseases
Key Trial Info
Start Date :
May 20 2025
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 10 2025
Estimated Enrollment :
55 Patients enrolled
Trial Details
Trial ID
NCT06587386
Start Date
May 20 2025
End Date
November 10 2025
Last Update
December 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Affiliated Hospital of Jiaxing University
Jiaxing, China